CRSP

Crispr Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 2/10
  • Value↓ 0/10
Crispr Therapeutics sales and earnings growth
CRSP Growth
Fair
  • Revenue Y/Y↓ -89.11%
  • EPS Y/Y↓ -37.78%
  • FCF Y/Y↓ -30.31%
Crispr Therapeutics gross and profit margin trends
CRSP Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -13856.50%
  • ROIC 5Y↓ -18.67%
Crispr Therapeutics net debt vs free cash flow
CRSP Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.9
  • Interest coverage↓ NA

Crispr Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks